$1.88
4.57% day before yesterday
Nasdaq, May 30, 10:02 pm CET
ISIN
US45257L1089
Symbol
IMMP
Sector
Industry

Immutep Ltd Sponsored ADR Stock price

$1.88
+0.17 9.94% 1M
-0.17 8.29% 6M
-0.29 13.36% YTD
-0.99 34.49% 1Y
-1.05 35.84% 3Y
+0.61 48.03% 5Y
-4.69 71.37% 10Y
Nasdaq, Closing price Fri, May 30 2025
-0.09 4.57%
ISIN
US45257L1089
Symbol
IMMP
Sector
Industry

Key metrics

Market capitalization $267.69m
Enterprise Value $166.34m
P/E (TTM) P/E ratio negative
EV/Sales (TTM) EV/Sales 5,544.75
P/S ratio (TTM) P/S ratio 8,923.08
P/B ratio (TTM) P/B ratio 24.67
Revenue growth (TTM) Revenue growth -82.35%
Revenue (TTM) Revenue $30.00k
EBIT (operating result TTM) EBIT $-35.25m
Cash position $102.43m
EPS (TTM) EPS $-0.02
P/E forward negative
P/S forward 72.12
EV/Sales forward 44.81
Short interest 2.87%
Show more

Is Immutep Ltd Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.

Immutep Ltd Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Immutep Ltd Sponsored ADR forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Immutep Ltd Sponsored ADR forecast:

Buy
100%

Financial data from Immutep Ltd Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
0.03 0.03
82% 82%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 5.33 5.33
11% 11%
17,767%
- Research and Development Expense 30 30
23% 23%
99,567%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -35 -35
17% 17%
-117,497%
Net Profit -28 -28
8% 8%
-94,033%

In millions USD.

Don't miss a Thing! We will send you all news about Immutep Ltd Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Immutep Ltd Sponsored ADR Stock News

Neutral
GlobeNewsWire
5 days ago
SYDNEY, AUSTRALIA, May 27, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces the investigator-initiated EFTISARC-NEO Phase II trial evaluating eftilagimod alfa (efti) with radiotherapy plus KEYTRUDA® (pembrolizumab) in the neoadjuvant setting for resectable ...
Positive
Seeking Alpha
24 days ago
Immutep's eftilagimod shows promising results in head and neck cancer, with a median overall survival of 17.6 months, significantly higher than what has been observed with other approaches. IMMP is well-capitalized with $146.3 million in liquidity, ensuring operations can continue without imminent dilution and funding issues. Despite promising phase 2 data, the fate of eftilagimod remains uncer...
Neutral
GlobeNewsWire
2 months ago
SYDNEY, AUSTRALIA , April 02, 2025 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces its management will present and participate in one-on-one meetings at the following investor conferences:
More Immutep Ltd Sponsored ADR News

Company Profile

Immutep Ltd. is a biotechnology company, which engages in the research and development of immunotherapeutic treatments for cancer and autoimmune diseases. Its product is IMP321, which involves in clinical development for the treatment of breast cancer and melanoma. The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.

Head office Australia
CEO Marc Voigt
Employees 31
Founded 1987
Website www.immutep.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today